Chemring Group (LSE:CHG) has been attracting attention for share price moves larger than the wider market. The Hampshire-based defence technology group has a record order book, new US contract wins and a chief executive handover under way, while heavy Investment in energetics capacity has lifted net debt.
Chemring Group supplies countermeasures, energetic materials, sensors and information products to defence, security and aerospace customers. Its shares trade on the Main Market of the London Stock Exchange, and the exchange lists the company in the FTSE 250, which places it inside the broader FTSE All-Share.
The stock has been showing high-beta characteristics. Beta is a historical measure of how strongly a share has tended to move relative to a benchmark index. A reading above 1 means larger swings than the market, up and down. It describes past price behaviour and is not a forecast of returns.
Why Chemring Group Is in Focus
On 24 September 2026, market data showed a one-year beta of 2.01 for Chemring (LSE:CHG). The shares have typically moved about twice as much as the benchmark over the past year. The same page gave a Market Capitalisation of about £1.45bn.
Exchange data showed the shares closing at 545.50p on 23 September, up 1.68% on the day. Market data showed a year-to-date gain of about 15% but a fall of about 4% over the previous month, showing movement in both directions.
What Does Chemring Group Do?
Chemring reports through two segments. Countermeasures & Energetics makes expendable decoys that protect aircraft and ships from guided missiles, plus propellants, missile components and devices used in satellite launch. Sensors & Information includes Roke, a UK science and engineering business, and US operations that make chemical and biological detection systems.
The group says it employs about 2,700 people, has production facilities in four countries and serves customers in more than 50 countries. Its financial year ends on 31 October.
What Has Been Happening Recently?
On 2 June 2026, Chemring published interim results for the six months to 30 April. Performance was in line with the board's expectations and full-year expectations were unchanged.
On 25 June, the group said its Philadelphia-based Alloy Surfaces business, previously classified as discontinued, had signed agreements with the US Department of War to restart sustained manufacturing. They comprise an IDIQ modification worth up to $300m over five years, with minimum awards of $35m a year for three years, and a $45m funding agreement. Deliveries should begin in early FY28, with no expected impact on FY26 or FY27.
On 1 July, US Subsidiary Chemring Sensors & Electronic Systems won a sole-source full-rate production contract for the Joint Biological Tactical Detection System, with a $48.8m ceiling and an initial $36.3m order. On 30 July, Chemring announced that chief executive Michael Ord will retire. Tom Newman, from Babcock International, joins as chief executive designate on 5 October 2026 and takes over on 1 January 2027.
What Are the Numbers Saying?
First-half Revenue rose 6.5% to £237.3m. The closing order book reached £1,399.4m, which the company described as the highest in its history. Chemring said 91% of expected 2026 revenue was either delivered or in the order book at 30 April.
Profit went the other way. Underlying operating profit fell 7.5% to £24.5m, cutting the Margin to 10.3% from 11.9%. Management cited Business mix and lower utilisation at Roke in Sensors & Information. Statutory operating profit fell 25% to £21.7m, partly reflecting a £6.7m Impairment on legacy Tennessee countermeasure operations. The Interim Dividend rose 4% to 2.8p.
Net Debt rose to £144.5m from £93.3m a year earlier, reflecting £44m of Capital Expenditure on energetics expansion in the half. That equals 1.47 times rolling 12-month underlying EBITDA. For the year to 31 October 2025, revenue was £497.5m and underlying operating profit £73.5m.
Why Is the Share Price Attracting Attention?
The facts: Chemring has a record order book, several US contract awards in quick succession and unchanged full-year expectations. Against that, first-half margins fell, net debt rose and a Leadership transition was announced. The shares carry a one-year beta of about 2.
Possible interpretations: One possible interpretation is that defence stocks are especially sensitive to geopolitical headlines and government spending decisions, so shifts in sentiment across the sector can move Chemring more sharply than the wider market. Some investors may view the energetics capacity build-out as a source of future growth, while others may focus on the execution risk and the higher borrowing that it brings. A chief executive change can also prompt reassessment, even when guidance is unchanged.
How Does the FTSE 250 and FTSE All-Share Context Matter?
As a FTSE 250 member, Chemring is part of the FTSE All-Share. Its beta is measured against a broad benchmark, and a high reading means the stock has amplified wider market moves while also reacting to company-specific news.
Mid-cap defence names also tend to trade as a group when investors reassess the sector, for example after defence-budget announcements. There is no evidence that index moves alone caused Chemring's recent price changes. Market data showed FTSE 250 trackers and specialist defence ETFs among holders, which may add sector-driven flows.
What Could Investors Watch Next?
Several scheduled or signposted events could influence sentiment:
- Leadership transition: Tom Newman is due to join as chief executive designate on 5 October 2026 before taking over on 1 January 2027.
- Year-end reporting: Chemring's financial year ends on 31 October. Last year it issued a post-close trading update on 10 November and full-year results on 9 December 2025; no 2026 dates were listed when checked.
- Energetics expansion: progress in Scotland, now commissioning, and Norway, alongside net debt.
- Sensors & Information recovery: whether utilisation at Roke improves after the weaker first half.
- Board changes: non-executive director Sarah Ellard will step down from the board on 31 December 2026.
The Bottom Line
Chemring's high-beta profile reflects a stock that has historically moved about twice as much as its benchmark, and 2026 has given investors plenty to react to. The group has reported a record £1.4bn order book, restarted a US decoy business with a multi-year contract and won a sole-source biological detection award. It is also absorbing lower first-half margins, net debt of £144.5m and a change of chief executive. Beta describes past sensitivity and does not predict direction. The next tests are the year-end trading update, progress on energetics capacity and Tom Newman's arrival in October.




_11_18_2026_14_55_02_703826.jpg)

Please wait processing your request...